Cameron Munter, a director at CareCloud, Inc. (NASDAQ:CCLD), recently sold 30,000 shares of the company’s common stock. The transaction, which took place on December 11, 2024, was completed at a price of $4.10 per share, totaling $122,999. The sale comes as CareCloud, with a market capitalization of $55.7 million, has shown strong momentum with a 357% return over the past year, despite a recent 13% decline in the past week. Following this sale, Munter now holds 159,000 shares directly. This move comes amid ongoing developments at CareCloud, a company known for its prepackaged software services. According to InvestingPro analysis, the company maintains a “GREAT” financial health score, with analysts setting a high price target of $6.00. InvestingPro subscribers have access to 12 additional investment tips and comprehensive analysis for CCLD.
In other recent news, CareCloud, a healthcare technology firm, has experienced a series of significant developments. Roth/MKM recently downgraded CareCloud’s stock from Buy to Neutral, setting a new price target of $3.50, citing weak growth projections for 2025 despite recent cost-cutting measures. This change in rating follows the company’s third-quarter revenue report of $28.5 million, meeting analyst expectations, and an increase in adjusted EBITDA to $6.8 million.
On the financial front, CareCloud announced the full repayment of its credit line and plans to resume dividend payments in March 2025. Despite a slight dip in revenue, the company’s third-quarter earnings report showed a significant increase in free cash flow, reaching $10.3 million, a 328% increase year-on-year.
In terms of strategic updates, CareCloud is focusing on growth and operational efficiency through its CareCloud CirrusAI platform and an in-house remote patient monitoring (RPM) solution. The company remains committed to its vision of transforming healthcare technology and delivering value to shareholders. These are the recent developments in CareCloud’s ongoing journey.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
